Longer recurrence‐free survival in a patient with metastatic renal cell carcinoma treated with temsirolimus

Temsirolimus did not demonstrate an efficacy advantage compared with sorafenib as second‐line therapy in patients with metastatic renal cell carcinoma (mRCC). Only a few patients achieved complete responses, and the median progression‐free survival rate remains short. We report one patient with mRCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Satoh, Tendo, Koie, Takuya, Horiguchi, Hirotaka, Tokui, Noriko, Narita, Satoshi, Ohyama, Chikara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715416/
https://www.ncbi.nlm.nih.gov/pubmed/29225833
http://dx.doi.org/10.1002/ccr3.1181
_version_ 1783283762904170496
author Satoh, Tendo
Koie, Takuya
Horiguchi, Hirotaka
Tokui, Noriko
Narita, Satoshi
Ohyama, Chikara
author_facet Satoh, Tendo
Koie, Takuya
Horiguchi, Hirotaka
Tokui, Noriko
Narita, Satoshi
Ohyama, Chikara
author_sort Satoh, Tendo
collection PubMed
description Temsirolimus did not demonstrate an efficacy advantage compared with sorafenib as second‐line therapy in patients with metastatic renal cell carcinoma (mRCC). Only a few patients achieved complete responses, and the median progression‐free survival rate remains short. We report one patient with mRCC who had a continuing response to temsirolimus.
format Online
Article
Text
id pubmed-5715416
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-57154162017-12-08 Longer recurrence‐free survival in a patient with metastatic renal cell carcinoma treated with temsirolimus Satoh, Tendo Koie, Takuya Horiguchi, Hirotaka Tokui, Noriko Narita, Satoshi Ohyama, Chikara Clin Case Rep Case Reports Temsirolimus did not demonstrate an efficacy advantage compared with sorafenib as second‐line therapy in patients with metastatic renal cell carcinoma (mRCC). Only a few patients achieved complete responses, and the median progression‐free survival rate remains short. We report one patient with mRCC who had a continuing response to temsirolimus. John Wiley and Sons Inc. 2017-10-18 /pmc/articles/PMC5715416/ /pubmed/29225833 http://dx.doi.org/10.1002/ccr3.1181 Text en © 2017 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Reports
Satoh, Tendo
Koie, Takuya
Horiguchi, Hirotaka
Tokui, Noriko
Narita, Satoshi
Ohyama, Chikara
Longer recurrence‐free survival in a patient with metastatic renal cell carcinoma treated with temsirolimus
title Longer recurrence‐free survival in a patient with metastatic renal cell carcinoma treated with temsirolimus
title_full Longer recurrence‐free survival in a patient with metastatic renal cell carcinoma treated with temsirolimus
title_fullStr Longer recurrence‐free survival in a patient with metastatic renal cell carcinoma treated with temsirolimus
title_full_unstemmed Longer recurrence‐free survival in a patient with metastatic renal cell carcinoma treated with temsirolimus
title_short Longer recurrence‐free survival in a patient with metastatic renal cell carcinoma treated with temsirolimus
title_sort longer recurrence‐free survival in a patient with metastatic renal cell carcinoma treated with temsirolimus
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715416/
https://www.ncbi.nlm.nih.gov/pubmed/29225833
http://dx.doi.org/10.1002/ccr3.1181
work_keys_str_mv AT satohtendo longerrecurrencefreesurvivalinapatientwithmetastaticrenalcellcarcinomatreatedwithtemsirolimus
AT koietakuya longerrecurrencefreesurvivalinapatientwithmetastaticrenalcellcarcinomatreatedwithtemsirolimus
AT horiguchihirotaka longerrecurrencefreesurvivalinapatientwithmetastaticrenalcellcarcinomatreatedwithtemsirolimus
AT tokuinoriko longerrecurrencefreesurvivalinapatientwithmetastaticrenalcellcarcinomatreatedwithtemsirolimus
AT naritasatoshi longerrecurrencefreesurvivalinapatientwithmetastaticrenalcellcarcinomatreatedwithtemsirolimus
AT ohyamachikara longerrecurrencefreesurvivalinapatientwithmetastaticrenalcellcarcinomatreatedwithtemsirolimus

Ejemplares similares